Sarcopenia (Myosteatosis) at Screening CT Colonoscopy in 79-Year-Old Woman With Subsequent Hip Fracture

Sarcopenia (Myosteatosis) at Screening CT Colonoscopy in 79-Year-Old Woman With Subsequent Hip Fracture: A & B. Image at L1 vertebral level without (A) and with (B) overlay of automated skeletal muscle segmentation (B, red). Intramuscular fat is present within paraspinal muscles (A, yellow circle). Mean muscle attenuation is similar for manually placed ROI (1.8 HU) and automated tool (3.9 HU), being markedly decreased for both approaches. Muscle cross-sectional area is relatively preserved when intramuscular fat is included.

C & D. CT images at L3 level without (C) and with (D) muscle segmentation demonstrate similar findings.

E. Hip radiograph demonstrates left intertrochanteric femoral fracture that occurred when patient fell 2 years later. Patient died 4 years after falling.


August 19, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), use of the L1 vertebral level — typically included on both chest and abdominal computed tomography (CT) examinations—rather than the L3 level expands the reach of opportunistic CT screening for sarcopenia.

“Automated CT-based measurements of muscle attenuation for myosteatosis at the L1 level compare favorably with previously-established L3 level measurements and clinical risk scores for predicting hip fractures and death,” wrote lead investigator Perry J. Pickhardt from the University of Wisconsin School of Medicine & Public Health in Madison. “Assessment for myopenia was less predictive of outcomes at both levels.”

Pickhardt and colleagues’ retrospective study included 9,223 patients (4,071 men, 5,152 women; mean age, 57 years) who underwent unenhanced low-dose abdominal CT. Muscle assessment for myosteatosis (mean attenuation) and myopenia (cross-sectional area) at the L1 and L3 levels was done via a previously validated fully-automated deep learning tool. Performance for predicting hip fractures and death was compared between L1 and L3 measures, then evaluated using FRAX score and Framingham risk score, respectively.

Among the 9,223 asymptomatic adults who underwent abdominal CT, muscle attenuation measurements at the L1 and L3 levels showed similar utility in predicting subsequent hip fracture and death. Meanwhile, muscle attenuation measurements at both levels showed comparable performance as established clinical risk scores.

The assessment of muscle attenuation (myosteatosis) performed better than the assessment of muscle area (myopenia) “likely due in part to the automated tool’s inclusion of intramuscular fat within the segmented areas,” the authors of this AJR article added.

For more information: www.arrs.org


Related Content

News | Digital Pathology

March 11, 2026 — Royal Philips has announced the expansion of its digital pathology portfolio with new cloud-enabled ...

Time March 26, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 25, 2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
News | Cybersecurity

March 23, 2026 —Sacumen has launched ConnectX, a unified AI platform that gives cybersecurity product companies full ...

Time March 25, 2026
arrow
News | Radiology Imaging

March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...

Time March 23, 2026
arrow
News | Radiology Business

March 1, 2026 — A new study from the Harvey L. Neiman Health Policy Institute found that practice turnover (i.e ...

Time March 19, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 18, 2026 — GE HealthCare and Springbok Analytics have entered a development agreement that will aim to leverage ...

Time March 18, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Subscribe Now